Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, controlled Phase 2 trial evaluating safety and efficacy of NSI-566 in ischemic stroke patients with half of their body partially paralyzed

Trial Profile

A randomized, double-blind, controlled Phase 2 trial evaluating safety and efficacy of NSI-566 in ischemic stroke patients with half of their body partially paralyzed

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NSI 566 (Primary)
  • Indications Paralysis; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seneca Biopharma
  • Most Recent Events

    • 07 Apr 2020 According to a Seneca Biopharma media release,This trial is an important step in the development of this therapy for the global market, especially China.The company remain on-track with our prior guidance, thanks to the physicians and clinical trial staff who have worked diligently to conduct this study, while maintaining their own safety and that of our patients during difficult circumstances brought about by the COVID-19 pandemic.
    • 07 Apr 2020 According to a Seneca Biopharma media release, as of March 31, 2020, follow-up assessments had been completed on 60% of the subjects in the trial and the company continues to expect data readout to be available during the second half of 2020, as previously disclosed.
    • 03 Apr 2020 According to a Seneca Biopharma media release, the company announced the completion of its new cell manufacturing facility in Suzhou, China which will be used to manufacture NSI-566 and used in this study.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top